217
Participants
Start Date
April 30, 2011
Primary Completion Date
February 28, 2017
Study Completion Date
February 28, 2017
Imprime PGG + cetuximab
Imprime PGG: 4 mg/kg and will be administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36) preceding the administration of cetuximab Cetuximab: initial dose will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2, administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36)
Cetuximab
Cetuximab: initial dose will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2, administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36)
New York Oncology, Hematology, P.C., Hudson
Hematology and Oncology Associates of Central NY, East Syracuse
Medizinisches Versorgungszentrum Ãrzteforum Seestrabe, Berlin
Ãrzteforum Henningsdorf Darmzentrum Oberhavel, Hennigsdorf
Virginia Oncology Associates, Newport News
Oncology and Hematology Associates of Southwest Virginia, Inc., dba Blue Ridge Cancer Care, Roanoke
Cancer Centers of the Carolinas, Spartanburg
MD Anderson Cancer Center, Orlando
AMPM Research Clinic, Miami Gardens
Klinikum Kassel GmbH Medizinische Klinik IV Onkologie, Hämatologie, Immunologie, Kassel, Hessen
Northwest Alabama Cancer Center, Florence
Tennessee Cancer Specialists, Knoxville
The Jones Clinic, Germantown
Schwerpunktpraxis für Hämatologie und Onkologie, Magdeburg
University of Louisville/James Brown Cancer Center, Louisville
Petruskrankenhaus Wuppertal, Klinik fuer Innere Medizin II- Gastroenterologie, Hepatologie und Diabetologie, Wuppertal
Toledo Community Oncology Program- Toledo Community Hospital, Toledo
Signal Point Hematology/Oncology, Middletown
Indiana University Cancer Center, Beech Grove
Henry Ford Health System, Detroit
Universitätsklinikum Köln - Studienzentrum der Klinik I für Innere Medizin, Koeln, Nordrhein Westfalen
Centre d' Oncologie de Gentilly, Nancy
University of Minnesota, Minneapolis
Illinois Cancer Specialists, Niles
Medical and Surgical Specialists, Galesburg
Ellis Fischel Cancer Center at University of Missouri- Columbia, Columbia
Oncology Hematology West PC dba Nebraska Cancer Specialists, Omaha
Ochsner Clinic Foundation, New Orleans
Highlands Oncology Group, Bentonville
Texas Oncology - Lewisville, Lewisville
Texas Oncology - Sherman, Sherman
Mary Crowley Cancer Research Center, Dallas
Texas Oncology - Dallas Presbyterian Hospital, Dallas
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
Texas Oncology - Tyler, Tyler
Texas Oncology - Fort Worth, Fort Worth
Texas Oncology Denton South, Denton
Cancer Care Centers of South Texas, San Antonio
Texas Oncology-Seton Williamson, Round Rock
Texas Oncology-Amarillo, Amarillo
Northern Utah Associates, Ogden
Universitaetsklinikum Ulm, Ulm
Kenmar Research Institute, Los Angeles
Providence St. Joseph Medical Center, Burbank
Pacific Medical Center, Anaheim
UCSD Moores Cancer Center, La Jolla
Comprehensive Blood and Cancer Center, Bakersfield
University of Hawaii Cancer Center, Honolulu
Providence Portland Medical Center, Portland
Willamette Valley Cancer Institute and Research Center, Eugene
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
Fundacion de Investigacion de Diego, San Juan
Lead Sponsor
HiberCell, Inc.
INDUSTRY